Argos Therapeutics
Argos Therapeutics Presents New Phase 2a Data on the Impact of Arcelis(TM) HIV Program on Viral Genetic Diversity
Published in AIDS Weekly and Law, April 8th, 2010
Argos Therapeutics announced the presentation of data from the Phase 2a trial of AGS-004, providing information on rebound viral genetic diversity in HIV patients treated with the personalized immunotherapy following antiretroviral therapy (ART) interruption. The data were discussed in a poster session at the Keystone Symposia Global Health Series HIV Vaccines meeting, held March 21-26, 2010 in Banff, Canada. AGS-004 is a product of the Company's Arcelis™ technology, and it is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is perfectly matched to each patient's unique HIV viral burden. Argos recently reported interim data from the Phase 2a trial, demonstrating...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly and Law
Source: AIDS Weekly and Law (2010-04-08)
More Articles from AIDS Weekly and Law
- HIV/AIDS
New HIV/AIDS study findings have been reported by K. Mori and co-researchers - Line 9 Films
'To Comfort You' Best Film in Beverly Hills Short Film Festival; Stars Susan Blakely and Pauley Perrette Share Best Actress Award - Methadone Therapy
New methadone therapy study findings have been reported from I. Afriandi et al - World Vision
Success against malaria bolsters case for further investment, new report shows - ...For A Cause, Inc.
Enjoy a Luxury Vacation and Help Pediatric AIDS and Breast Cancer Organizations - Adenosine Therapy
Research reports from University of California provide new insights into adenosine therapy - More from this issue of AIDS Weekly and Law
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
